Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm, Multi-center Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# Toripalimab Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma Cannot Undergo Surgical Resection and TACE

NCT04926532 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT04926532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04926532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm, Multi-center Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# Toripalimab Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma Cannot Undergo Surgical Resection and TACE
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 1, 2019
Completion date
December 31, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma